Now, a disposable device to identify aggressive breast cancersSeptember 29th, 2010 - 5:52 pm ICT by ANI
Washington, Sep 29 (ANI): Scientists have developed a new disposable device based on advances in microfluidics that may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin).
Aggressive breast cancers with poor prognosis typically have abnormal levels of the protein HER2 (the tyrosine kinase human epidermal growth factor receptor 2). The new elastomeric, rubber-like device is designed to efficiently capture cancer cells overexpressing HER2 in circulating blood.
Finding a way to identify these cells is medically relevant because HER2 positive patients with early breast cancer have been found to significantly benefit from treatment with Herceptin or trastuzumab, the humanized monoclonal antibody against HER2, which can lower recurrence risk by about half.
In the study Benjamin Thierry and colleagues at the Ian Wark Research Institute at the University developed a plastic-based disposable microfluidic device offering several improvements for capturing circulating tumor cells.
The device is designed to take advantage of the features of an organic silicone found in contact lenses and shampoos called polydimethylsiloxane (PDMS), which is compatible with soft molding techniques, transparent, and permeable to gasses.
The device is significantly easier and cheaper to make than the prior microfabricated one. The major challenge associated with PDMS use in biodiagnostic applications is its lack of chemical reactivity.
The team used a novel plasma-based polymerisation process to overcome that problem. The process creates a durable polymeric layer on the device’s surface containing a high number of reactive molecules, which can readily be used to attach proteins able to capture cancer cells but not normal blood cells.
With a commonly used breast cancer cell line (SK-BR-3) as a model for cells overexpressing HER2, Dr. Thierry’s device demonstrated an 80 percent immuno-capture efficacy of HER positive cells from full blood in model and validation studies.
“Microfluidic-based devices offer a unique opportunity to efficiently isolate CTCs from patient’s blood, thereby opening a window on the pathophysiology of cancer and its progression. We hope that our device will provide a fast, reliable and affordable methodology to establish HER2 status for breast cancer patients,” concluded Thierry.
The findings were described in the American Institute of Physics’ journal Biomicrofluidics. (ANI)
- Genetic pathways involved in breast cancer identified - Mar 04, 2011
- New 'nanodrug' can attack breast cancer cells from the inside out - Mar 30, 2011
- Target therapy 'boosts longevity in HER2-positive breast cancer patients' - Dec 12, 2009
- New potential target for breast cancer therapy identified - Dec 23, 2010
- 'Wonderdrug' keeps breast cancer away - Feb 25, 2011
- New device to efficiently identify and 'grab' circulating cancer cells - Mar 08, 2011
- Combo therapy may overcome Herceptin-resistant breast cancer - Mar 14, 2011
- New therapy shows promising result for HER2-positive metastatic disease - Oct 09, 2010
- Carbon nanotube device can rapidly diagnose cancer, HIV - Mar 30, 2011
- New drug effective against breast tumours - Dec 13, 2009
- Erectile dysfunction drug could enhance delivery of herceptin to brain tumours - May 08, 2010
- Key enzyme that controls growth of breast cancer cells identified - Nov 19, 2010
- Now, a quick and affordable microfluidic HIV test - Jul 17, 2010
- How breast cancer cells dodge immune system and survive - Feb 02, 2011
- Super vaccine could knock out 70 percent of cancers - Dec 13, 2011
Tags: abnormal levels, advanced breast cancer, blood cells, breast cancer, breast cancer patients, breast cancers, cancer cell, cancer cells, chemical reactivity, circulating tumor cells, disposable device, epidermal growth factor, epidermal growth factor receptor, growth factor receptor, molding techniques, monoclonal antibody, poor prognosis, reactive molecules, recurrence risk, tyrosine kinase